Source
29 developments in the corpus
Latest
Everything in the corpus, newest first.
OCT 18, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Stimuli‐responsive depots for postoperative cancer therapy often treat therapeutic payloads as passive cargo, resulting in premature leakage and limited on‐demand activati
OCT 18, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Oxaliplatin (L‐OHP) is a first‐line chemotherapeutic agent for advanced colorectal cancer (CRC) and postoperative adjuvant therapy. However, acquired L‐OHP resistance rema
OCT 18, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Methylselenol (CH 3 SeH) is not only a key selenium (Se) metabolite but also a potent therapeutic molecule. Chemical tools for stimulus‐responsive delivery of CH 3 SeH sho
OCT 15, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Late recurrence in gynecologic malignancies is associated with tumor dormancy and persistent minimal residual disease (MRD). Although current treatments reduce proliferati
OCT 11, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT High‐risk estrogen receptor positive (ER+) early breast cancer (EBC) is managed with endocrine therapies and cyclin‐dependent kinase (CDK) 4/6 inhibitors, although no stan
OCT 11, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Trastuzumab is the standard first‐line targeted therapy for human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer (GC). Unfortunately, its clinical effic
OCT 11, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) is driven by nutrient stress through incompletely defined epigenetic mechanisms. This study demonstrates that lipid
OCT 8, 2026 · JOURNAL ARTICLE
Advanced Science
ABSTRACT Combination therapies are key to overcoming resistance to androgen receptor (AR) signaling inhibitors in prostate cancer. Current paradigms for developing synergistic ther